Exosomics Siena

What Exosomics Siena does

Exosomics Siena (legal entity Exosomics SpA, headquartered in Siena, Italy) is a privately held biotechnology company specializing in extracellular vesicle (EV) / exosome-based liquid biopsy technologies for cancer diagnostics. Its core offerings are two pre-analytical enrichment platforms — SeleCTEV, a peptide-based kit that purifies tumor-derived DNA from plasma, and SoRTEV, an antibody-based kit that isolates RNA from tumor-enriched exosomes — both targeting tumor-specific surface markers such as EpCAM, HER2, and PD-L1 to reduce background from normal cell-derived EVs. The company's flagship clinical product, the Prostate IntelliScore (EPI) test, was launched in 2018 and received FDA Breakthrough Device Designation in 2019, marking it as the first commercial-grade EV-based diagnostic test.

The company operates a B2B sales-led go-to-market, distributing pre-analytical kits, reference standards, and EV isolation/characterization tools directly to diagnostic laboratories, hospitals, research institutions, and CRO clients globally — primarily via its wholly-owned subsidiary HansaBioMed Life Sciences (established in North Europe in 2007), which also offers contract research services supporting industrial and academic EV research. In 2024, the group established LongEVity Bioscience as a second wholly-owned subsidiary to commercialize exosome-based skin care products under proprietary brands PHYTOXOME (Italian-made) and JUVEV EXOGLOW (South Korean import), extending the core EV technology into the consumer beauty and wellness market and representing a diversification away from the pure-research and clinical-oncology base. Reported operating geographies center on Italy and broader Europe (with HansaBioMed covering Northern Europe), and additional sectors such as regenerative medicine, nutrition, and agriculture are identified on the company website as future applications of the EV platform.

Name

Exosomics Siena

Legal name

Exosomics SpA

Website

https://exosomics.eu

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

251–500 employees

Short description

Exosomics Siena is an Italian biotech company developing extracellular vesicle (exosome) based pre-analytical enrichment kits and diagnostics for cancer liquid biopsy, serving oncology laboratories and research institutions globally through its subsidiaries HansaBioMed Life Sciences and the newly established consumer-cosmetics arm LongEVity Bioscience.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics / Liquid Biopsy

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Liquid biopsy diagnostics
• Exosome isolation kits
• Tumor EV enrichment
• Extracellular vesicle research
• Pre-analytical platforms

Headquarters

HQ city

Siena

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pre-analytical EV Enrichment Kits: Sale ofSeleCTEV DNA Enrichment Kit and SoRTEV RNA Enrichment Kit for tumor EV enrichment from plasma samples. These are pre-analytical tools sold to laboratories for research and diagnostic applications.
2. Reference Standards and Controls: Sale of reference standards and controls for EV-based analytical procedures, as well as methods for standardized plasma collection suitable for biobanking.
3. Subsidiary Products (HansaBioMed Life Sciences): HansaBioMed sells the largest variety of products in the EV field globally including EV standards, tools for EV isolation and characterization, dedicated kits and antibodies. Also offers contract research organization (CRO) services.
4. Cosmetic/Wellness Products (LongEVity Bioscience): Sale of exosome-based skin care products through PHYTOXOME (proprietary Italian brand) and JUVEV EXOGLOW (South Korean brand) targeting beauty and wellness markets.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Exosomics develops and sells pre-analytical kits (SeleCTEV and SoRTEV) that selectively enrich tumor-derived extracellular vesicles (EVs) from plasma for use in liquid biopsy cancer diagnostics. The SeleCTEV kit uses peptide-based affinity capture to purify circulating cell-free DNA from tumor-enriched EVs, while SoRTEV uses antibody-based immunoaffinity to isolate RNA from tumor-enriched exosomes. The company also sells EV reference standards, isolation/characterization tools, and antibodies through its subsidiary HansaBioMed Life Sciences, and offers CRO services for EV research.

Product overview

Exosomics Siena offers a portfolio of EV (extracellular vesicle/exosome) based products focused on liquid biopsy for cancer diagnostics. The core products are SeleCTEV (peptide-based DNA enrichment) and SoRTEV (antibody-based RNA enrichment), two preanalytical platforms that enable selective tumor EV enrichment from plasma for downstream molecular diagnostics. Through its subsidiary HansaBioMed Life Sciences, the company provides the largest variety of EV standards, isolation tools, characterization kits, and antibodies globally. Through another subsidiary, LongEVity Bioscience, it offers consumer wellness products under the PHYTOXOME and JUVEV EXOGLOW brands for the beauty and cosmetics market. The company also provides standardized plasma collection methods for biobanking.

Differentiator

Problem solved

Functional benefit

Brands

• PHYTOXOME: LongEVity proprietary brand designed and produced in Italy offering high quality skin care products based on exosomes having potent anti-age and regenerative activity.
• JUVEV EXOGLOW

Products and services

• SeleCTEV DNA Enrichment Kit (EXO-SEL-LVR) Pre-analytical kit using peptide-based affinity capture to selectively enrich tumor-derived extracellular vesicles from plasma (0.5–2 ml input) and purify circulating cell-free DNA and tumor-originated DNA for downstream molecular diagnostics and liquid biopsy applications. Intended for diagnostic and research laboratories.
• SoRTEV RNA Enrichment Kit (EXO-SOR-LV) Pre-analytical kit using antibody-based immunoaffinity capture to isolate RNA (mRNA, miRNA, lncRNA) contained in tumor-enriched exosomes from plasma (0.5–2 ml input), optimized for downstream molecular analysis. Intended for diagnostic and research laboratories.
• EV Reference Standards and Controls Reference standards and controls for extracellular vesicle-based analytical procedures, distributed by subsidiary HansaBioMed Life Sciences to support EV research standardization and quality control.
• Standardized Plasma Collection for Biobanking Methods and procedures to obtain standardized plasma collection suitable for biobanking and advanced diagnostic procedures involving extracellular vesicle analysis.
• PHYTOXOME Proprietary brand of high-quality skin care products based on exosomes with potent anti-age and regenerative activity, designed and produced in Italy under LongEVity Bioscience.
• JUVEV EXOGLOW Innovative brand of skin care products imported from South Korea, offering an exclusive line based on selected active ingredients and CICA exosomes, sold through LongEVity Bioscience.

Quantifiable outcome

• Combining exosomal RNA/DNA with ctDNA increases mutant copy detection by up to 10-fold, significantly improving detection accuracy in early-stage disease
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• LongEVity BiosciencecoreStrategic or Co-development Partner · 1 January 2024LongEVity Bioscience is the youngest company within the Exosomics Group, established in Italy in 2024 to offer high-quality exosome-based products and ingredients addressed to beauty and wellness markets. Targets retail cosmetic market with two innovative brands: PHYTOXOME (proprietary Italian brand) and JUVEV EXOGLOW (South Korean brand).
• Dutch NWO Perspectief Cancer-ID ProgramminorStrategic or Co-development Partner · 1 January 2020Multi-institution collaboration under the Dutch NWO Perspectief Cancer-ID program focused on developing and evaluating detection and characterization techniques to distinguish tumor-derived EVs from non-EV particles and other EVs. Participants included academic and research institutions.
• HansaBioMed Life SciencescoreStrategic or Co-development Partner · 1 January 2007HansaBioMed Life Sciences (HBM) is a subsidiary of Exosomics, established in North Europe in 2007. It is the oldest exosome-focused company and the only EV/Exosomes focused Life Sciences company. HBM sells globally the largest variety of products in the EV field including EV standards, tools for EV isolation and characterization, dedicated kits and antibodies, and offers CRO services supporting R&D needs and pilot studies in the EV field.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Others

• Lonza: Strategic investor and bioprocess/CDMO partner from the 2017 financing round. Functions as a manufacturing enabler and channel partner rather than direct competitor, with growing exosome-related service offerings.

Broad incumbents

• QIAGEN: Sample-prep technology leader with significant liquid biopsy and circulating nucleic-acid portfolio (QIAamp products, exosome isolation kits). Overlaps with Exosomics in pre-analytical sample preparation for oncology diagnostics, but QIAGEN serves a much broader customer base beyond oncology.
• Guardant Health: Leading ctDNA-based liquid biopsy company (Guardant360, Guardant Reveal). Same end market (oncology liquid biopsy) and same clinical use cases (therapy monitoring, residual disease detection), but uses cell-free DNA rather than tumor-derived EVs. Established commercial and reimbursement scale.
• Thermo Fisher Scientific: Dominant life-sciences tools provider with growing EV/Exosome product lines (e.g., Total Exosome Isolation reagents, EV characterization antibodies) and downstream cell therapy and liquid biopsy solutions. Operates broadly across the same lab-tooling category but is not specialized in tumor-derived EV enrichment.

Emerging players

• Evox Therapeutics: UK-based exosome engineering company developing engineered EVs for drug delivery. Different end application (therapeutics vs. diagnostics) but shared core competency in EV cargo engineering and surface modification relevant to Exosomics' selective enrichment approach.
• Codiak BioSciences: Engineered exosome (engEx) platform for therapeutics; while therapeutic-focused rather than diagnostic, leverages the same foundational EV biology and engineering expertise. Partial overlap as the broader exosome technology ecosystem evolves toward clinical applications.

Direct peers

• Miltenyi Biotec: Major life-science tools company offering exosome/EV isolation products, including antibody-based capture reagents. Competes head-to-head with Exosomics' immunoaffinity enrichment kits (SeleCTEV, SoRTEV) and HBM's antibody-based isolation tools.
• System Biosciences (SBI): Sells EV isolation kits, exosome standards, characterization tools, and antibodies — the same consumables catalog as HansaBioMed Life Sciences. Direct overlap with the HBM product portfolio across research-use EV tools.
• Bio-Techne (ExosomeDx): Acquired ExosomeDx in 2018; ExosomeDx's EPI prostate exosome test is the most direct competitor to Exosomics' Prostate IntelliScore. Same product category (EV-based prostate cancer diagnostic), same regulatory pathway (FDA Breakthrough Device Designation), same customer profile (urology labs).
• Mursla Bio: UK-based EV diagnostics company developing multi-cancer early detection via tissue-specific EV signatures. Directly comparable technology platform (tumor-derived EVs for liquid biopsy) and similar end-market focus on early cancer detection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/exosomics-siena-s-p-a

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exosomics Siena